Focus on human microbiome to fight liver cirrhosis

22 European institutions join forces in MICROB-PREDICT to improve the prevention and treatment of chronic liver disease (cirrhosis). We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensated cirrhosis), when such decompensated cirrhosis will progress to acute-on-chronic liver failure (ACLF), and a patient’s individual treatment response. Based on such biomarkers, we strive to develop novel diagnostic tools for earlier and better patient stratification and to establish personalised and effective treatment strategies.

Learn more

Who are the people behind the science of MICROB-PREDICT?

Watch this video to meet the coordinator, the patient representative, our leading researchers, clinicians, and the management team. Feel free to like and share to promote our research and efforts. We are all working together to improve the lives of patients suffering from decompensated cirrhosis and ACLF.

More news

MICROB-PREDICT Symposium connected to EASL School on Hepatology 2021 in Frankfurt

Management of acute-on-chronic liver failure - Course director: Prof. Jonel Trebicka - Location: Goethe University Frankfurt // Date: 01.07.2021

More events